Human Antibodies for Emerging Virus Infections
Previously Aired on February 14th, 2023
Human monoclonal antibody technology has matured to the point that rapid and large-scale discovery efforts yield thousands of antibody candidates, many of which exhibit extraordinary antiviral potency and unprecedented breadth against circulating field strains.
Capitalizing on this capability, the AHEAD100 initiative was launched in 2021 to help prevent future pandemics by discovering, testing, and stockpiling human monoclonal antibodies for the 100 most likely causes of future epidemics.
In this webinar, James E. Crowe, Jr., M.D., Director of the Vanderbilt University Vaccine Center, talks about this proactive initiative as well as how antibody discovery can now be conducted with extraordinary speed and precision, yielding molecules that can be used in diverse applications, including prevention, therapy, diagnosis, and vaccine characterization.
You will learn about:
- State-of-the-art approaches for isolation of human monoclonal antibodies
- Structural determinants of molecular recognition of virus surface proteins by human antibodies
- Current knowledge of the size and complexity of human antibody repertoires in the response to viruses
Intended audience:
- Grad students, postdocs and academics interested in the infectious disease research field
- Lab managers and directors
- Virologists
- Epidemiologists
Gain access to the webinar by filling in the form below.
